377 related articles for article (PubMed ID: 10361103)
1. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL
Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103
[TBL] [Abstract][Full Text] [Related]
2. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
3. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.
MacDonald KP; Rowe V; Filippich C; Thomas R; Clouston AD; Welply JK; Hart DN; Ferrara JL; Hill GR
Blood; 2003 Mar; 101(5):2033-42. PubMed ID: 12393418
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation.
Reddy P; Teshima T; Hildebrandt G; Duffner U; Maeda Y; Cooke KR; Ferrara JL
Blood; 2002 Nov; 100(9):3429-31. PubMed ID: 12384449
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease.
Pan L; Delmonte J; Jalonen CK; Ferrara JL
Blood; 1995 Dec; 86(12):4422-9. PubMed ID: 8541530
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of murine leukemia following non-myeloablative conditioning with naïve or G-CSF mobilized blood or bone marrow stem cells.
Weiss L; Or R; Slavin S; Naparstek E; Reich S; Abdul-Hai A
Cancer Immunol Immunother; 2004 Apr; 53(4):358-62. PubMed ID: 14605765
[TBL] [Abstract][Full Text] [Related]
8. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient.
Reddy V; Hill GR; Pan L; Gerbitz A; Teshima T; Brinson Y; Ferrara JL
Transplantation; 2000 Feb; 69(4):691-3. PubMed ID: 10708136
[TBL] [Abstract][Full Text] [Related]
9. Long-term engraftment, graft-vs.-host disease, and immunologic reconstitution after experimental transplantation of allogeneic peripheral blood cells from G-CSF-treated donors.
Pan L; Bressler S; Cooke KR; Krenger W; Karandikar M; Ferrara JL
Biol Blood Marrow Transplant; 1996 Oct; 2(3):126-33. PubMed ID: 9199755
[TBL] [Abstract][Full Text] [Related]
10. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
11. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model.
Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L
Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478
[TBL] [Abstract][Full Text] [Related]
13. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
Zhao J; Zhao XY; Huang XJ
Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
[TBL] [Abstract][Full Text] [Related]
14. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease.
Krijanovski OI; Hill GR; Cooke KR; Teshima T; Crawford JM; Brinson YS; Ferrara JL
Blood; 1999 Jul; 94(2):825-31. PubMed ID: 10397751
[TBL] [Abstract][Full Text] [Related]
15. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect.
Clouthier SG; Cooke KR; Teshima T; Lowler KP; Liu C; Connolly K; Ferrara JL
Biol Blood Marrow Transplant; 2003 Sep; 9(9):592-603. PubMed ID: 14506661
[TBL] [Abstract][Full Text] [Related]
16. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
17. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
Chang YJ; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte colony-stimulating factor affects the distribution and clonality of TRGV and TRDV repertoire of T cells and graft-versus-host disease.
Xuan L; Wu X; Zhang Y; Fan Z; Ling Y; Huang F; Zhang F; Zhai X; Liu Q
J Transl Med; 2011 Dec; 9():215. PubMed ID: 22171570
[TBL] [Abstract][Full Text] [Related]
19. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?
Morris ES; MacDonald KP; Hill GR
Blood; 2006 May; 107(9):3430-5. PubMed ID: 16380448
[TBL] [Abstract][Full Text] [Related]
20. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
